
Lofexidine
CAS No. 31036-80-3
Lofexidine( —— )
Catalog No. M20672 CAS No. 31036-80-3
Lofexidine is a selective α2-receptor agonist Lofexidine reduces narcotic withdrawal symptoms.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 27 | In Stock |
![]() ![]() |
50MG | 77 | In Stock |
![]() ![]() |
100MG | Get Quote | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameLofexidine
-
NoteResearch use only, not for human use.
-
Brief DescriptionLofexidine is a selective α2-receptor agonist Lofexidine reduces narcotic withdrawal symptoms.
-
DescriptionLofexidine is a selective α2-receptor agonist Lofexidine reduces narcotic withdrawal symptoms.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetAdrenergic Receptor
-
Recptorα2 receptor
-
Research AreaNeurological Disease
-
Indicationopioid withdrawal symptoms in adults
Chemical Information
-
CAS Number31036-80-3
-
Formula Weight259.13
-
Molecular FormulaC11H12Cl2N2O
-
Purity>98% (HPLC)
-
SolubilityDMSO:62.5 mg/mL (241.19 mM)
-
SMILESCC(Oc1c(Cl)cccc1Cl)C1=NCCN1
-
Chemical Name2-(1-(26-dichlorophenoxy)ethyl)-45-dihydro-1H-imidazole
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Gorodetzky CW Walsh SL Martin PRet al.A phase III randomized multi-center double blind placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal[J].Drug Alcohol Depend. 2017 Jul 1;176:79-88.
molnova catalog



related products
-
Medetomidine hydroch...
A potent, highly selective α2-adrenoceptor agonist with Ki of 1.08 nM; used as both a surgical anesthetic and analgesic.
-
nifenalol.HCl
Nifenalol is a antagonist of β-adrenergic receptor.
-
Anisodamine Hydrobro...
Anisodamine Hydrobromide is an anticholinergic and α1-adrenergic receptor antagonist used in the treatment of acute circulatory shock.